* The report provides brief overview of
Asklepios BioPharmaceutical, Inc.
Asklepios wants to buy a stake of about 10.1%, which would be considered a blocking minority due to Rhoen's bylaws.
* Review of current pipeline of
Asklepios BioPharmaceutical, Inc.
Last year, German healthcare group Fresenius SE & Co KGaA (ETR:FRE) failed to acquire Rhoen for EUR3.1bn (USD4bn) as
Asklepios purchased its initial interest in the firm.
7 March 2013 - The German Federal Cartel Office today said on its website it had extended till 15 March the deadline by which it needs to decide on
Asklepios Kliniken GmbH's plan to purchase up to 10.1% in fellow hospitals operator Rhoen-Klinikum AG (ETR:RHK).
Last year, German healthcare group Fresenius SE & Co KGaA (ETR:FRE) made an unsuccessful attempt to take over Rhoen-Klinikum as
Asklepios got on its way by acquiring a stake of less than 10% in the mutual target.Country: GermanySector: HealthcareTarget: Rhoen-Klinikum AGBuyer:
Asklepios Kliniken GmbHType: StakebuildingStatus: Bidding
The German newspaper was told that management and supervisory board of Fresenius had decided to drop the takeover pursuit due to opposition from
Asklepios Kliniken GmbH.